Evaluation of Reader Training Processes

This study is designed to evaluate the agreement between florbetapir F 18 scan interpretation in the clinic and by expert readers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Research Site

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Scan obtained for clinical reasons

Exclusion criteria

None

Treatment and study plan

florbetapir F 18

Drug

No study drug will be administered in this study - scans previously acquired in the course of clinical practice.

Other names: 18F-AV-45, Amyvid, florbetapir

Primary outcomes

Agreement Between Expert Panel and Clinical Practice Reads

Time frame: Scan acquired 50-60 minutes post injection

Agreement between expert panel consensus scan interpretations and clinical practice reader scan interpretations was calculated as a weighted Kappa value across all cases and all clinical practice readers.

Sponsors and collaborators

Lead sponsor

Avid Radiopharmaceuticals

Industry

Registry information

Official study title

Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads

Important dates

Study start: 2014
Primary completion: 2014
Study completion: 2014
First posted: Jan 31, 2014
Registry last updated: Sep 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed